177 related articles for article (PubMed ID: 37340243)
1. Intraperitoneal paclitaxel combined with FOLFOX/CAPOX plus bevacizumab for colorectal cancer with peritoneal carcinomatosis (the iPac-02 trial): study protocol of a single arm, multicenter, phase 2 study.
Murono K; Yokoyama Y; Nozawa H; Sasaki K; Emoto S; Matsuzaki H; Kashiwabara K; Ishigami H; Gohda Y; Yamaguchi H; Kitayama J; Ishihara S
Int J Colorectal Dis; 2023 Jun; 38(1):173. PubMed ID: 37340243
[TBL] [Abstract][Full Text] [Related]
2. Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial.
Murono K; Nagata H; Ishimaru K; Emoto S; Kaneko M; Hiyoshi M; Sasaki K; Otani K; Shuno Y; Nishikawa T; Tanaka T; Hata K; Kawai K; Nozawa H; Muro K; Ishihara S
Cancer Chemother Pharmacol; 2019 Jan; 83(1):145-150. PubMed ID: 30386886
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of intraperitoneally administered paclitaxel for colorectal cancer with peritoneal metastases.
Murono K; Nozawa H; Nagata H; Ishimaru K; Sonoda H; Emoto S; Kaneko M; Sasaki K; Otani K; Kawai K; Muro K; Ishihara S
Int J Colorectal Dis; 2020 Oct; 35(10):1945-1949. PubMed ID: 32495229
[TBL] [Abstract][Full Text] [Related]
4. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases: protocol of the multicentre, open-label, phase II, INTERACT-II trial.
van de Vlasakker VCJ; Guchelaar NAD; van den Heuvel TBM; Lurvink RJ; van Meerten E; Bax RJF; Creemers GM; van Hellemond IEG; Brandt-Kerkhof ARM; Madsen EVE; Nederend J; Koolen SLW; Nienhuijs SW; Kranenburg O; de Hingh IHJT; Verhoef C; Mathijssen RHJ; Burger JWA; ;
BMJ Open; 2024 Jan; 14(1):e077667. PubMed ID: 38238055
[TBL] [Abstract][Full Text] [Related]
6. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).
Rovers KP; Bakkers C; Simkens GAAM; Burger JWA; Nienhuijs SW; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; Ayez N; de Boer NL; van Meerten E; Tuynman JB; Kusters M; Sluiter NR; Verheul HMW; van der Vliet HJ; Wiezer MJ; Boerma D; Wassenaar ECE; Los M; Hunting CB; Aalbers AGJ; Kok NFM; Kuhlmann KFD; Boot H; Chalabi M; Kruijff S; Been LB; van Ginkel RJ; de Groot DJA; Fehrmann RSN; de Wilt JHW; Bremers AJA; de Reuver PR; Radema SA; Herbschleb KH; van Grevenstein WMU; Witkamp AJ; Koopman M; Haj Mohammad N; van Duyn EB; Mastboom WJB; Mekenkamp LJM; Nederend J; Lahaye MJ; Snaebjornsson P; Verhoef C; van Laarhoven HWM; Zwinderman AH; Bouma JM; Kranenburg O; van 't Erve I; Fijneman RJA; Dijkgraaf MGW; Hemmer PHJ; Punt CJA; Tanis PJ; de Hingh IHJT; ;
BMC Cancer; 2019 Apr; 19(1):390. PubMed ID: 31023318
[TBL] [Abstract][Full Text] [Related]
7. Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.
Kobayashi D; Ishigami H; Kanda M; Tanaka C; Yamaguchi H; Kitayama J; Kodera Y
Oncology; 2020; 98(1):48-52. PubMed ID: 31487733
[TBL] [Abstract][Full Text] [Related]
8. First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II).
Lurvink RJ; Rauwerdink P; Rovers KP; Wassenaar ECE; Deenen MJ; Nederend J; Huysentruyt CJR; van 't Erve I; Fijneman RJA; van der Hoeven EJRJ; Seldenrijk CA; Constantinides A; Kranenburg O; Los M; Herbschleb KH; Thijs AMJ; Creemers GM; Burger JWA; Wiezer MJ; Nienhuijs SW; Boerma D; de Hingh IHJT
BMJ Open; 2021 Mar; 11(3):e044811. PubMed ID: 33785492
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of intraperitoneal irinotecan combined with palliative systemic chemotherapy in patients with colorectal peritoneal metastases.
van Eerden RAG; de Boer NL; van Kooten JP; Bakkers C; Dietz MV; Creemers GM; Buijs SM; Bax R; de Man FM; Lurvink RJ; Diepeveen M; Brandt-Kerkhof ARM; van Meerten E; Koolen SLW; de Hingh IHJT; Verhoef C; Mathijssen RHJ; Burger JWA
Br J Surg; 2023 Oct; 110(11):1502-1510. PubMed ID: 37467389
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis.
Takahara N; Nakai Y; Ishigami H; Saito K; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Yamashita H; Isayama H; Seto Y; Koike K
Invest New Drugs; 2021 Feb; 39(1):175-181. PubMed ID: 32772340
[TBL] [Abstract][Full Text] [Related]
11. Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial.
de Boer NL; Brandt-Kerkhof ARM; Madsen EVE; Diepeveen M; van Meerten E; van Eerden RAG; de Man FM; Bouamar R; Koolen SLW; de Hingh IHJT; Bakkers C; Rovers KP; Creemers GM; Deenen MJ; Kranenburg OW; Constantinides A; Mathijssen RHJ; Verhoef C; Burger JWA; ;
BMJ Open; 2019 Dec; 9(12):e034508. PubMed ID: 31818845
[TBL] [Abstract][Full Text] [Related]
12. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885
[TBL] [Abstract][Full Text] [Related]
13. BEV-IP: Perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis.
Willaert W; Van Der Speeten K; Liberale G; Ceelen W
BMC Cancer; 2015 Dec; 15():980. PubMed ID: 26673788
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.
Roohullah A; Wong HL; Sjoquist KM; Gibbs P; Field K; Tran B; Shapiro J; Mckendrick J; Yip D; Nott L; Gebski V; Ng W; Chua W; Price T; Tebbutt N; Chantrill L
World J Gastroenterol; 2015 May; 21(17):5352-8. PubMed ID: 25954110
[TBL] [Abstract][Full Text] [Related]
15. Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?
Chan DY; Syn NL; Yap R; Phua JN; Soh TI; Chee CE; Nga ME; Shabbir A; So JB; Yong WP
J Gastrointest Surg; 2017 Mar; 21(3):425-433. PubMed ID: 27981493
[TBL] [Abstract][Full Text] [Related]
16. A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial.
Glockzin G; Rochon J; Arnold D; Lang SA; Klebl F; Zeman F; Koller M; Schlitt HJ; Piso P
BMC Cancer; 2013 Feb; 13():67. PubMed ID: 23391248
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Chia DKA; Sundar R; Kim G; Ang JJ; Lum JHY; Nga ME; Goh GH; Seet JE; Chee CE; Tan HL; Ho J; Ngoi NYL; Lee MXW; Muthu V; Chan GHJ; Pang ASL; Ang YLE; Choo JRE; Lim JSJ; Teh JL; Lwin A; Soon Y; Shabbir A; So JBY; Yong WP
Ann Surg Oncol; 2022 Dec; 29(13):8597-8605. PubMed ID: 36070113
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
19. Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study.
Pintova S; Dharmupari S; Moshier E; Zubizarreta N; Ang C; Holcombe RF
Cancer Chemother Pharmacol; 2019 Sep; 84(3):591-598. PubMed ID: 31203390
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Intraperitoneal Paclitaxel Plus Intravenous Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) for Gastric Cancer with Peritoneal Metastasis.
Kang SH; Min SH; Kim JW; Lee E; Park SW; Lee S; Oh HJ; Park YS; Lee YJ; Kim JW; Ahn SH; Suh YS; Lee KW; Lee HS; Kim HH
Ann Surg Oncol; 2022 Aug; 29(8):5084-5091. PubMed ID: 35322307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
